Efficacy of Regional Citrate versus Heparin Anticoagulation in Continuous Renal Replacement Therapy

Author:

Bhandari Gaurav1,Choudhury Debarun1,Bhalla Anil Kumar1,Malik Manish1,Gupta Anurag1,Bhargava Vinant1,Tiwari Vaibhav1,Chadha Shiv1,Gupta Ashwani1,Rana Devinder Singh1

Affiliation:

1. Department of Nephrology, Sir Ganga Ram Hospital, New Delhi, India

Abstract

Background Continuous renal replacement therapy (CRRT) is used in hemodynamically unstable patients with acute kidney injury (AKI). Heparin, the most commonly used anticoagulant, has a significant bleeding risk and is associated with heparin-induced thrombocytopenia. Regional citrate anticoagulation is an alternative anticoagulation strategy in CRRT. Materials and Methods A randomized controlled trial was conducted in the Intensive Care Unit over one year, from October 2020 to September 2021, in patients with AKI requiring CRRT. Fifty-two patients were randomized into two groups: group 1 received regional citrate anticoagulation, and group 2 received heparin anticoagulation. Results The mean age in group 1 was 50.46 years, while it was 49.35 years in group 2. The mean filter lifespan in group 1 was 45.11 hours, while in group 2, it was 26.11 hours and was statistically significant (P < 0.001). The mean effective delivered RRT dose was higher in group 1 (26 ml/kg/hour) compared to group 2 (24.23 ml/kg/hour), which was statistically significant (P < 0.001). Bleeding episodes were higher in group 2 than in group 1 (42.3% vs 11.5%), which was statistically significant (P = 0.027). The RCA group had various electrolyte and metabolic complications, but these were not statistically significant. Conclusion Regional citrate anticoagulation is better than heparin anticoagulation in terms of filter lifespan, effective delivered RRT dose, bleeding episodes, and metabolic complications.

Publisher

Scientific Scholar

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3